Cagrilintide 5mg/vial Effectively Suppresses Appetite And Increases Energy Expenditure

Cagrilintide 5mg/bottle core introduction

Pharmaceutical-grade long-acting amylin analogue | Made in China amylin receptor agonist 5mg/vial

Common name : Cagrilintide

Research and development code : AM833

Structural type : Acylated peptide based on natural amylin sequence optimization

Target : Amylin receptor (AMYR)

Purity : ≥99.0% (HPLC detection)

Appearance : White lyophilized powder

Storage : Store frozen at -20℃ away from light; after thawing, refrigerate at 2-8℃.

Core advantages and functions

Cagrilintide is a long-acting amylin receptor agonist designed based on the optimized molecular structure of natural amylin , and is an important representative of the next generation of weight management drugs . By specifically activating the amylin receptor , it exerts potent appetite suppression, delayed gastric emptying, and weight regulation effects in the central nervous system and peripheral tissues . It has demonstrated remarkable weight loss effects and metabolic improvement potential in studies of obesity, type 2 diabetes, and related metabolic syndromes , making it a key tool molecule for research on weight management mechanisms and the development of drugs for metabolic diseases .

✅Precise Mechanism of Action :

Central appetite suppression : Acts on the arcuate nucleus and parabrachial nucleus of the hypothalamus and the nucleus of the solitary tract in the brainstem , producing a strong and lasting feeling of satiety by activating amylin receptors.

Peripheral metabolic regulation :

Significantly slows gastric emptying rate and prolongs the time food stays in the stomach.

Inhibits postprandial glucagon secretion and improves blood sugar control

slightly increases energy expenditure and promotes the "browning" of white adipose tissue.

Long-acting pharmacokinetic characteristics : Modification with fatty acid side chains significantly prolongs the half-life, supporting a once-weekly dosing regimen .

Receptor selectivity : It has high affinity and selectivity for the amylin receptor, avoiding the risk of cross-reactivity with the calcitonin receptor.

✅Quality advantages of Chinese manufacturers :

Advanced synthetic modification techniques :

By employing solid-phase peptide synthesis combined with proprietary fatty acid side-chain targeted modification technology , the modification efficiency is ≥95%.

Optimized acylation reaction conditions ensure precise linkage of C18 diacid fatty acid chains.

Overall synthesis yield ≥80%, with large-scale production capacity reaching the kilogram level.

Multidimensional purification and quality control system :

Four-stage purification process : ion exchange → hydrophobic chromatography → molecular sieve → reversed-phase HPLC

Purity control : RP-HPLC purity ≥ 99.0%, SEC-HPLC monomer content ≥ 98.5%.

Structural confirmation :

Precise determination of molecular weight by mass spectrometry (MS)

Nuclear magnetic resonance (NMR) verification of fatty acid chain linkage sites

Circular dichroism (CD) analysis of secondary structure stability

Key impurity control :

Relevant peptide impurities: deleted sequences, oxidation products, deamidation products

Process impurities: fatty acid chain residues, organic solvent residues

Bioactivity verification :

In vitro receptor binding assay : Determination of affinity (KD value) for amylin receptor.

Functional cAMP experiment : Verifying receptor agonistic activity (EC50 value)

In vivo pharmacodynamic model : Validating weight loss effects using a diet-induced obesity (DIO) animal model.

Stability study :

Complete accelerated stability testing (40℃/75%RH, 6 months).

Long-term stability data (-20℃, 24 months)

Light stability and temperature cycling test

✅Product Features :

High potency and long-lasting effect : A single dose can produce an appetite-suppressing effect that lasts for up to a week.

High selectivity : Superior selectivity for amylin receptors compared to natural amylin

Good safety profile : Clinical studies have shown good safety and tolerability.

Synergistic potential : It has a synergistic effect with GLP-1 receptor agonists, significantly enhancing the weight loss effect.

Usage and Storage Guide

1. Reconstitution and preparation :

Special solvent :

The accompanying sterile reconstitution diluent (pH 7.4-8.0 buffer) must be used.

The use of ordinary saline, sterile water for injection, or other non-dedicated solvents is strictly prohibited.

Standard preparation procedure :

Slowly inject 1.0 mL of the special diluent along the inner wall of the vial.

Gently rotate the vial horizontally in your palm for 2-3 minutes.

A clear or slightly opalescent solution was obtained at 5 mg/mL.

Perform a second dilution with the same diluent or physiological saline containing 0.1% BSA.

Key points to note :

Avoid violent shaking and vortexing during the dissolving process.

The reconstituted solution should be used within 1 hour.

Before administration, visually inspect the solution to ensure it is clear and free of particles.

2. Storage conditions :

Unreconstituted lyophilized powder :

Store frozen at -20℃, shelf life 24 months.

Store frozen at -80℃; shelf life 36 months.

Avoid repeated freeze-thaw cycles

Reconstituted drug solution :

for 24 hours when refrigerated at 2-8℃.

Do not freeze.

Transportation conditions :

Dry ice transport (below -78℃)

Vacuum Insulated Packaging

Equipped with temperature recording device

3. Research and application plan :

Preclinical animal studies :

Core model :

Diet-induced obesity (DIO) mouse/rat model

Zucker obese rat model

A model of metabolic syndrome induced by a high-fat diet

Dosage regimen :

Subcutaneous injection : 0.1-1.0 mg/kg, 1-2 times per week.

Intraperitoneal injection : 0.5-2.0 mg/kg, 1-2 times per week.

Treatment plan :

Short-term efficacy: 4-8 weeks

Long-term efficacy: 12-24 weeks

Monitoring indicators :

Weight, food intake, body composition

Blood sugar, insulin, blood lipids

Energy expenditure, respiratory quotient

Mechanism of action study :

Receptor occupancy and signaling pathways

Central appetite regulation circuit

Peripheral metabolic regulation mechanism

Synergistic effect with other metabolic drugs

4. Experimental Design Suggestions :

Dosage exploration : Set 3-4 dose gradients

Control group setup :

Solvent control group

Positive control group (e.g., liraglutide)

Combination therapy group (in combination with GLP-1RA)

Observation time points : Dynamic monitoring at multiple time points

Why choose Cagrilintide made in China?

Technical advantages :

Mastering core fatty acid side chain modification technology

Possessing completely independent intellectual property rights

A complete technology platform from R&D to production

Production facilities that meet international cGMP standards

Quality Guarantee :

Purity ≥ 99.0%, single impurities ≤ 0.5%

Batch consistency RSD < 5%

Complete quality study documents

Quality comparability study with the original drug

Application Support :

Provide detailed technical information

Experimental design support

Data analysis assistance

Customized services

Cost advantage :

Large-scale production reduces costs

Compared to imported products, they have a clear price advantage.

Stable supply and timely delivery

Flexible packaging specifications

Research and application directions

Obesity research :

Appetite regulation mechanism

Weight control strategies

Energy metabolism regulation

Improved body composition

Metabolic diseases :

Type 2 diabetes

Metabolic syndrome

Nonalcoholic fatty liver disease

Cardiovascular metabolic risk

Combined treatment :

Synergistic effect with GLP-1RA

Combination with other metabolic regulators

Fixed-dose combination therapy development

Personalized treatment plan

Translational medicine :

Preclinical safety evaluation

Pharmacokinetic studies

Exploring the optimal dosing regimen

Biomarker discovery

Preclinical research data reference

Pharmacodynamic data :

Weight loss effect : In the DIO model, a dose of 0.3-1.0 mg/kg can produce dose-dependent weight loss.

Feeding suppression : significantly reduces 24-hour food intake.

Metabolic improvements : Improved insulin sensitivity, reduced fasting blood glucose

Safety : Wide therapeutic window, no obvious toxic reactions.

Pharmacokinetics :

Half-life: Approximately 120 hours

Bioavailability: ≥85% for subcutaneous injection

Volume of distribution: High binding rate to plasma proteins

Clearance: via peptidase degradation and renal excretion

Summarize

Cagrilintide, a new generation of long-acting amylin receptor agonists , holds significant scientific value and promising clinical applications in weight management and the treatment of metabolic diseases . Chinese manufacturers, through advanced synthetic modification technologies, rigorous quality control systems, and comprehensive research data , provide researchers worldwide with high-quality, highly active research tools . The potent, long-acting properties and favorable safety profile of this product offer strong support for research and drug development in obesity and related metabolic diseases.

Need anything, please contact us

Hot Tags: cagrilintide 5mg/vial effectively suppresses appetite and increases energy expenditure, China cagrilintide 5mg/vial effectively suppresses appetite and increases energy expenditure manufacturers, suppliers, factory, AOD9604 Ideal For Competition Prep Peak Weeks, ace 031 1mg, buy aod 9604 pills, peptide cjc ipamorelin, Alternative to GHRP 6, hgh ipamorelin